NCT04580381 - Real World Effectiveness of Natalizumab Extended Interval Dosing in a French Cohort | Biotech Hunter

Enrollment

500

Participants

Timeline

Start Date

September 1, 2020

Primary Completion Date

October 1, 2021

Study Completion Date

October 30, 2021

Conditions

Multiple Sclerosis, Relapsing-Remitting

Interventions

DRUG

Natalizumab Injection [Tysabri]

Natalizumab infusion interval according to local practice defining the patient's group

Trial Locations (5)

Department of Neurology, CHU de Caen, Caen

Department of Neurology, CHU Toulouse Purpan, Toulouse

Department of Neurology, Percy Military Hospital, Clamart

Department of Neurology, CHU Bobigny-Avicenne, Bobigny

Department of Neurology, CHU Nice, Nice